Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19050989 | 0.99 | KMT2A (0.59) | KMT2AEPHX2LMNASMN1; SMN2FABP7 | |
| SCHEMBL4556421 | 0.99 | KMT2A (0.59) | KMT2AEPHX2LMNASMN1; SMN2FABP7 | |
| SCHEMBL30094147 | 0.99 | KMT2A (0.59) | KMT2AEPHX2LMNASMN1; SMN2FABP7 | |
| SCHEMBL20173568 | 0.99 | KMT2A (0.59) | KMT2AEPHX2LMNASMN1; SMN2FABP7 | |
| SCHEMBL13671094 | 0.99 | KMT2A (0.59) | KMT2AEPHX2LMNASMN1; SMN2FABP7 | |
| SCHEMBL30094166 | 0.99 | KMT2A (0.59) | KMT2AEPHX2LMNASMN1; SMN2FABP7 | |
| SCHEMBL4557536 | 0.99 | KMT2A (0.59) | KMT2AEPHX2LMNASMN1; SMN2FABP7 | |
| SCHEMBL4557033 | 0.99 | KMT2A (0.59) | KMT2AEPHX2LMNASMN1; SMN2FABP7 | |
| SCHEMBL31548843 | 0.99 | KMT2A (0.59) | KMT2AEPHX2LMNASMN1; SMN2FABP7 | |
| SCHEMBL31010196 | 0.91 | KMT2A (0.60) | KMT2AEPHX2LMNASMN1; SMN2FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352625-A1 | MUTANTS OF COCAINE ESTERASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-11-21 | — | — | US | claimed |
| US-10160960-B2 | Mutants of cocaine esterase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-12-25 | — | — | US | claimed |
| US-20160177277-A1 | MUTANTS OF COCAINE ESTERASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-06-23 | — | — | US | claimed |
| WO-2015021187-A1 | MUTANTS OF COCAINE ESTERASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-02-12 | — | — | WO | claimed |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-12202829-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| EP-2320954-A1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | Bracco Imaging S.p.A (IT) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010010079-A1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | BRACCO IMAGING SPA (IT) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010079-A1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | BRACCO IMAGING SPA (IT) | 2010-01-28 | — | — | WO | disclosed |
| EP-1879906-A4 | REVERSIBLE NUCLEOTIDE TERMINATORS AND USES THEREOF | ADVANCED GENETIC ANALYSIS CORP (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1879906-A2 | REVERSIBLE NUCLEOTIDE TERMINATORS AND USES THEREOF | AB Advanced Genetic Analysis Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006074351-A2 | REVERSIBLE NUCLEOTIDE TERMINATORS AND USES THEREOF | AGENCOURT PERSONAL GENOMICS (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | KMT2A 1606/4885EPHX2 736/4885LMNA 4516/4885 |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | KMT2A 1606/4885EPHX2 736/4885LMNA 4516/4885 |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | KMT2A 1606/4885EPHX2 736/4885LMNA 4516/4885 |
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | MMP3, MMP7, MMP9 | KMT2A 1798/4885EPHX2 1692/4885LMNA 1584/4885 |
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | G6PC1, GAA, GBA3 | KMT2A 3263/4885EPHX2 3941/4885LMNA 144/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | KMT2A 2470/4885EPHX2 2856/4885LMNA 1814/4885 |
| US-12202829-B2 | Heterocyclic compound | XIAP, BIRC5, BIRC3 | KMT2A 3878/4885EPHX2 3111/4885LMNA 1743/4885 |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | KMT2A 2470/4885EPHX2 2856/4885LMNA 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.